RNA cargo in motion: The exosomal connection to head and neck cancers
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-May-2025 18:09 ET (5-May-2025 22:09 GMT/UTC)
Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA highlighting the role of exosomal RNA (exRNA) in head and neck cancers (HNCs). Exosomal RNAs, including miRNA, mRNA, and lncRNA, are secreted by tumor cells and play a pivotal role in cancer progression by modulating key signaling pathways such as NF-κB, EGFR, and PI3K/AKT/mTOR. These exRNAs influence the tumor microenvironment, promote metastasis, and contribute to immune evasion and therapy resistance. The study underscores the potential of exRNA-based liquid biopsy through saliva and blood samples for early diagnosis and treatment monitoring, presenting a promising avenue for precision oncology in HNC management.
Cancer treatment has advanced significantly, focusing on targeted approaches that destroy tumor cells while sparing healthy tissue. Researchers at JAIST have developed magnetic nanoparticles that can be directed to tumors using a magnet and then heated with a laser to destroy cancer cells. In mouse models, this targeted technique successfully eliminated tumors entirely. This innovative method provides a more precise and less toxic alternative to traditional treatments, paving the way for more effective cancer therapies.
A new paper in the Journal of Breast Imaging indicates that breast cancer mortality rates have stopped declining in women older than age 74, and reconfirms that breast cancer mortality rates have stopped falling in women younger than age 40. This finding for older women is new.
New research shows that a common type of diabetes medication could help cancer patients make a better long-term recovery. Many cancer patients go on to develop heart failure - because of the cancer itself and also due to chemotherapy.
But a new study shows that a type of diabetes drug, called an SGLT2 inhibitor, may help protect the heart during and after cancer treatment.
This is the first time that any medication has been shown to be beneficial in reducing heart failure or heart failure hospitalisation in cancer patients and survivors.
Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells hijack various cellular functions to find and exploit energy and other resources, including a group of enzymes that help normal cells maintain a balance of energy.
These enzymes, called creatine kinases (CK), allow cells to transport energy produced at the mitochondria to where it is needed throughout the cell. Studies of breast cancer cells have highlighted the importance of a type of CK called ubiquitous mitochondrial creatine kinase (uMtCK).
New research published in Structure will serve as the foundation for a collaborative team of Sanford Burnham Prebys and Mayo Clinic investigators to design and develop novel small molecules that selectively inhibit uMtCK to treat breast cancer.Pancreatic cancer that spreads to the liver is especially difficult to treat because the liver naturally suppresses immune responses, creating an environment where cancer can evade detection and thrive.
UCLA researchers have developed a nanoparticle that carries a combination treatment with an mRNA vaccine and a small immune-boosting molecule to the liver, reprogramming it to attack pancreatic cancer.
Lab studies showed the therapy shrank tumors that spread to the liver, prevented new ones and activated immune memory cells that could help stop pancreatic cancer from coming back.
Scientists have discovered a strategy to fight back against norovirus, a leading cause of gastroenteritis worldwide. Their new study, published in Science Translational Medicine, identifies powerful antibodies capable of neutralizing a wide range of norovirus strains. The finding could lead to the design of broadly effective norovirus vaccine, as well as the development of new therapeutic antibodies for the treatment of norovirus-associated gastroenteritis.